Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer

Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and efficacy of AMR with primary prophylactic pegfilgra...

Descripció completa

Dades bibliogràfiques

Autors principals:	Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2023-12-01
Col·lecció:	Thoracic Cancer
Matèries:	amrubicin febrile neutropenia pegfilgrastim second‐line chemotherapy small cell lung cancer
Accés en línia:	https://doi.org/10.1111/1759-7714.15140
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!